Tags: Drug.

Cabazitaxel (previously XRP-6258 trade name Jevtana) is a semi-synthetic derivative of a natural taxoid. It was developed by Sanofi-Aventis and was approved by the U.S. Food and Drug Administration (FDA) for the treatment of hormone-refractory prostate cancer on June 17 2010.

Cabazitaxel.png
ATC prefix
L01
ATC suffix
CD04
CAS number
183133-96-2
ChEBI
63584
DrugBank
DB06772
FDA UNII code
51F690397J
IUPAC name
(1S2S3R4S7R9S10S12R15S)-4-(Acetyloxy)-15-[(2R3S)-3-[(tert-butoxy)carbonyl]amino-2-hydroxy-3-phenylpropanoyl]oxy-1-hydroxy-912-dimethoxy-10141717-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.0310.047]heptadec-13-ene-2-yl benzoate
PubChem
9854073

Loading...

This page contains content from the copyrighted Wikipedia article "Cabazitaxel"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.